CDKN2A and neoplasm: MYH9, 10 and 14 mutant tumors also exhibited mutational inactivation and/or copy loss of commonly altered tumor suppressors CDKN2A (p16), FAT1, or NOTCH1, and infrequently altered TGFβ pathway components, TGF-B-R2 or SMAD4.